Financial Analysis: Mangoceuticals (NASDAQ:MGRX) vs. LifeStance Health Group (NASDAQ:LFST)

LifeStance Health Group (NASDAQ:LFST) and Mangoceuticals (NASDAQ:MGRX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Earnings and Valuation

This table compares LifeStance Health Group and Mangoceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42 billion	3.48	$9.66 million	$0.13	99.77
Mangoceuticals	$460,000.00	18.89	-$20.64 million	($1.01)	-0.40

LifeStance Health Group has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.5% of LifeStance Health Group shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 3.5% of LifeStance Health Group shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for LifeStance Health Group and Mangoceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0	4	6	1	2.73
Mangoceuticals	1	0	0	0	1.00

LifeStance Health Group presently has a consensus price target of $12.88, indicating a potential downside of 0.73%. Given LifeStance Health Group’s stronger consensus rating and higher possible upside, analysts plainly believe LifeStance Health Group is more favorable than Mangoceuticals.

Profitability

This table compares LifeStance Health Group and Mangoceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	3.19%	3.39%	2.33%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

Volatility & Risk

LifeStance Health Group has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Summary

LifeStance Health Group beats Mangoceuticals on 12 of the 15 factors compared between the two stocks.

About LifeStance Health Group

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.